Diadexus Inc (DDXS) 1.3500 $DDXS
Diadexus, Inc. and Sonic Healthcare USA Sign National Agreement for PLAC(R) Activity Test
Marketwire Canada - Mon May 23, 8:00AM CDT
Partnering With Fifth Largest U.S. Laboratory Service Provider to Launch Broadly the PLAC(R) Activity Test, an FDA-Cleared Test for Coronary Heart Disease Risk Assessment
Diadexus, Inc. Reports First Quarter 2016 Financial Results
Marketwired - Thu Apr 28, 3:15PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 2016 and provided an update on its business.
Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update
Marketwired - Mon Apr 18, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced preliminary financial performance metrics for the first quarter ended March 31, 2016 and provided an update on its business.
Updated - Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
Marketwired - Mon Mar 28, 6:17PM CDT
Diadexus, Inc. (OTCQB: DDXS) -- The enclosed Condensed Statements of Operations and the Condensed Balance Sheets are updated for appropriate classification of three line items.
Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
Marketwired - Mon Mar 28, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the fourth quarter and year ended December 31, 2015 and provided an update on its business.
What Awaits Akers Biosciences (AKER) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:10AM CDT
Akers Biosciences Inc (AKER) is expected to report fourth-quarter 2015 earnings results on Mar 30.
AMZN: 727.65 (+1.01), AXDX: 14.32 (+0.15), AKER: 2.08 (+0.09)
LeMaitre Vascular (LMAT) Looks Good: Stock Rises 8%
Zacks Equity Research - Zacks Investment Research - Mon Dec 07, 7:30AM CST
LeMaitre Vascular, Inc. (LMAT) was a big mover last session, as the company saw its shares rise slightly over 8% on the day.
LMAT: 15.09 (+0.15)
Bovie Medical (BVX) Catches Eye: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Thu Nov 12, 7:30AM CST
Bovie Medical Corporation (BVX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BVX: 1.72 (+0.04)
VWR Corp Looks Good on Strategic Initiatives: Add to Portfolio
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 1:15PM CST
On Nov 9, 2015, we issued an updated research report on VWR Corporation (VWR).
SRDX: 23.30 (-0.51), NXTM: 20.99 (-0.12), VWR: 30.05 (-0.20)
Diadexus, Inc. Presents New PLAC(R) Activity Data From the REGARDS Study at 2015 American Heart Association Scientific Sessions
Marketwired - Tue Nov 10, 8:01AM CST
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced a poster presentation at the 2015 American Heart Association (AHA) Scientific Sessions taking place November 7-11, 2015 in Orlando, FL.
Hill-Rom (HRC) Poised on Organic Growth, Long-Term Targets
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 1:30PM CST
On Nov 6, 2015, we updated our research report on medical device company Hill-Rom Holdings, Inc. (HRC).
SRDX: 23.30 (-0.51), NXTM: 20.99 (-0.12), HRC: 51.22 (+0.12)
Hill-Rom Beats on Q4 Earnings, Revenues; FY16 View Strong
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 9:15AM CST
Hill-Rom Holdings, Inc. (HRC) reported fourth-quarter fiscal 2015 adjusted earnings per share (EPS) of 83 cents, up 12.2% from the year-ago quarter.
SRDX: 23.30 (-0.51), OFIX: 47.25 (+1.82), HRC: 51.22 (+0.12)
BioScrip Q3 Loss Wider than Expected; Strategic Plan in Focus
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 12:45PM CST
BioScrip, Inc. (BIOS) reported adjusted net loss from continuing operations of 19 cents per share in the third quarter of 2015.
SRDX: 23.30 (-0.51), BIOS: 2.93 (-0.07), HRC: 51.22 (+0.12)
Alere Lags Q3 Earnings, Revenue Estimates; Cuts 2015 View
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 12:30PM CST
Alere Inc. (ALR) reported adjusted earnings (including share based compensation) of 51 cents per share in the third quarter of 2015.
SRDX: 23.30 (-0.51), ALR: 42.68 (-0.12), HRC: 51.22 (+0.12)
NxStage Medical Q3 Loss Narrower than Expected, View Up
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 12:55PM CST
NxStage Medical Inc. (NXTM) reported adjusted loss of 3 cents per share in the third quarter of 2015.
ICUI: 108.13 (-0.02), NXTM: 20.99 (-0.12), HRC: 51.22 (+0.12)
Diadexus, Inc. Reports Third Quarter 2015 Financial Results
Marketwired - Mon Oct 26, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the nine months and quarter ended September 30, 2015, and provided an overview of recent corporate achievements and milestones.
Diadexus, Inc. Names Jonathan Ruais as Vice President of Marketing
Marketwired - Tue Oct 13, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that Jonathan Ruais has joined the Company as Vice President of Marketing. Mr. Ruais brings over 15 years of leadership experience to Diadexus, including nearly 10 years as a highly accomplished marketing executive in the medical industry. In his new role at Diadexus, Mr. Ruais will be responsible for developing and executing the Company's marketing programs, including helping drive awareness and adoption of PLAC(R) Activity within the hospital and lab channels and supporting the launch of proADM for acute episodes of heart failure.
Diadexus, Inc. and OriGene Technologies Sign Exclusive License Agreement for the Development and Commercialization of PLAC(R) ELISA in Asia
Marketwired - Tue Sep 08, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it has entered into an exclusive, license and supply agreement granting OriGene Technologies, Inc. ("OriGene"
rights to develop and commercialize Diadexus' proprietary PLAC(R) ELISA in certain Asian countries ("the Territory".
Diadexus, Inc. Reports Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the six months and quarter ended June 30, 2015, and provided an update on the business.
Diadexus, Inc. and Sonic Healthcare USA Sign National Agreement for PLAC(R) Activity Test
Marketwire Canada - Mon May 23, 8:00AM CDT
Partnering With Fifth Largest U.S. Laboratory Service Provider to Launch Broadly the PLAC(R) Activity Test, an FDA-Cleared Test for Coronary Heart Disease Risk Assessment
Diadexus, Inc. Reports First Quarter 2016 Financial Results
Marketwired - Thu Apr 28, 3:15PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 2016 and provided an update on its business.
Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update
Marketwired - Mon Apr 18, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced preliminary financial performance metrics for the first quarter ended March 31, 2016 and provided an update on its business.
Updated - Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
Marketwired - Mon Mar 28, 6:17PM CDT
Diadexus, Inc. (OTCQB: DDXS) -- The enclosed Condensed Statements of Operations and the Condensed Balance Sheets are updated for appropriate classification of three line items.
Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
Marketwired - Mon Mar 28, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the fourth quarter and year ended December 31, 2015 and provided an update on its business.
What Awaits Akers Biosciences (AKER) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:10AM CDT
Akers Biosciences Inc (AKER) is expected to report fourth-quarter 2015 earnings results on Mar 30.
AMZN: 727.65 (+1.01), AXDX: 14.32 (+0.15), AKER: 2.08 (+0.09)
LeMaitre Vascular (LMAT) Looks Good: Stock Rises 8%
Zacks Equity Research - Zacks Investment Research - Mon Dec 07, 7:30AM CST
LeMaitre Vascular, Inc. (LMAT) was a big mover last session, as the company saw its shares rise slightly over 8% on the day.
LMAT: 15.09 (+0.15)
Bovie Medical (BVX) Catches Eye: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Thu Nov 12, 7:30AM CST
Bovie Medical Corporation (BVX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BVX: 1.72 (+0.04)
VWR Corp Looks Good on Strategic Initiatives: Add to Portfolio
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 1:15PM CST
On Nov 9, 2015, we issued an updated research report on VWR Corporation (VWR).
SRDX: 23.30 (-0.51), NXTM: 20.99 (-0.12), VWR: 30.05 (-0.20)
Diadexus, Inc. Presents New PLAC(R) Activity Data From the REGARDS Study at 2015 American Heart Association Scientific Sessions
Marketwired - Tue Nov 10, 8:01AM CST
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced a poster presentation at the 2015 American Heart Association (AHA) Scientific Sessions taking place November 7-11, 2015 in Orlando, FL.
Hill-Rom (HRC) Poised on Organic Growth, Long-Term Targets
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 1:30PM CST
On Nov 6, 2015, we updated our research report on medical device company Hill-Rom Holdings, Inc. (HRC).
SRDX: 23.30 (-0.51), NXTM: 20.99 (-0.12), HRC: 51.22 (+0.12)
Hill-Rom Beats on Q4 Earnings, Revenues; FY16 View Strong
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 9:15AM CST
Hill-Rom Holdings, Inc. (HRC) reported fourth-quarter fiscal 2015 adjusted earnings per share (EPS) of 83 cents, up 12.2% from the year-ago quarter.
SRDX: 23.30 (-0.51), OFIX: 47.25 (+1.82), HRC: 51.22 (+0.12)
BioScrip Q3 Loss Wider than Expected; Strategic Plan in Focus
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 12:45PM CST
BioScrip, Inc. (BIOS) reported adjusted net loss from continuing operations of 19 cents per share in the third quarter of 2015.
SRDX: 23.30 (-0.51), BIOS: 2.93 (-0.07), HRC: 51.22 (+0.12)
Alere Lags Q3 Earnings, Revenue Estimates; Cuts 2015 View
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 12:30PM CST
Alere Inc. (ALR) reported adjusted earnings (including share based compensation) of 51 cents per share in the third quarter of 2015.
SRDX: 23.30 (-0.51), ALR: 42.68 (-0.12), HRC: 51.22 (+0.12)
NxStage Medical Q3 Loss Narrower than Expected, View Up
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 12:55PM CST
NxStage Medical Inc. (NXTM) reported adjusted loss of 3 cents per share in the third quarter of 2015.
ICUI: 108.13 (-0.02), NXTM: 20.99 (-0.12), HRC: 51.22 (+0.12)
Diadexus, Inc. Reports Third Quarter 2015 Financial Results
Marketwired - Mon Oct 26, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the nine months and quarter ended September 30, 2015, and provided an overview of recent corporate achievements and milestones.
Diadexus, Inc. Names Jonathan Ruais as Vice President of Marketing
Marketwired - Tue Oct 13, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that Jonathan Ruais has joined the Company as Vice President of Marketing. Mr. Ruais brings over 15 years of leadership experience to Diadexus, including nearly 10 years as a highly accomplished marketing executive in the medical industry. In his new role at Diadexus, Mr. Ruais will be responsible for developing and executing the Company's marketing programs, including helping drive awareness and adoption of PLAC(R) Activity within the hospital and lab channels and supporting the launch of proADM for acute episodes of heart failure.
Diadexus, Inc. and OriGene Technologies Sign Exclusive License Agreement for the Development and Commercialization of PLAC(R) ELISA in Asia
Marketwired - Tue Sep 08, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it has entered into an exclusive, license and supply agreement granting OriGene Technologies, Inc. ("OriGene"
rights to develop and commercialize Diadexus' proprietary PLAC(R) ELISA in certain Asian countries ("the Territory". Diadexus, Inc. Reports Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the six months and quarter ended June 30, 2015, and provided an update on the business.
